Haque R, Huston CD, Hughes M, Houpt E, Petri WA Jr, 2003. Amebiasis. N Engl J Med 348: 1565–1573.
Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg F, Keystone JS, Pandey P, Cetron MS, 2006. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 354: 119–130.
Walsh JA, 1986. Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Rev Infect Dis 8: 228–238.
Cohen HG, Reynolds TB, 1975. Comparison of metronidazole and chloroquine for the treatment of amoebic liver abscess. A controlled trial. Gastroenterology 69: 35–41.
Rossignol JF, Kabil SM, El-Gohary Y, Younis AM, 2007. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 101: 1025–1031.
Irusen EM, Jackson TF, Simjee AE, 1992. Asymptomatic intestinal colonization by pathogenic Entamoeba histolytica in amebic liver abscess: prevalence, response to therapy, and pathogenic potential. Clin Infect Dis 14: 889–893.
Fujishima T, Nishise S, Ichihara M, Kobayashi S, Takeuchi T, 2010. Difficulties in the treatment of intestinal amoebiasis in mentally disabled individuals at a Rehabilitation Institution for the Intellectually Impaired in Japan. Chemotherapy 56: 348–352.
Asgharpour A, Gilchrist C, Baba D, Hamano S, Houpt E, 2005. Resistance to intestinal Entamoeba histolytica infection is conferred by innate immunity and Gr-1+ cells. Infect Immun 73: 4522–4529.
Houpt ER, Glembocki DJ, Obrig TG, Moskaluk CA, Lockhart LA, Wright RL, Seaner RM, Keepers TR, Wilkins TD, Petri WA Jr, 2002. The mouse model of amebic colitis reveals mouse strain susceptibility to infection and exacerbation of disease by CD4+ T cells. J Immunol 169: 4496–4503.
Tchouaffi-Nana F, Ballard TE, Cary CH, Macdonald TL, Sifri CD, Hoffman PS, 2010. Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces. Antimicrob Agents Chemother 54: 2767–2774.
Downey AS, Graczyk TK, Sullivan DJ, 2009. In vitro activity of pyrvinium pamoate against Entamoeba histolytica and Giardia intestinalis using radiolabelled thymidine incorporation and an SYBR Green I-based fluorescence assay. J Antimicrob Chemother 64: 751–754.
Samarawickrema NA, Brown DM, Upcroft JA, Thammapalerd N, Upcroft P, 1997. Involvement of superoxide dismutase and pyruvate:ferredoxin oxidoreductase in mechanisms of metronidazole resistance in Entamoeba histolytica. J Antimicrob Chemother 40: 833–840.
Wassmann C, Hellberg A, Tannich E, Bruchhaus I, 1999. Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. J Biol Chem 274: 26051–26056.
Bansal D, Sehgal R, Chawla Y, Mahajan RC, Malla N, 2004. In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar. Ann Clin Microbiol Antimicrob 3: 27–31.
Seifert K, Duchene M, Wernsdorfer WH, Kollaritsch H, Scheiner O, Wiedermann G, Hottkowitz T, Eibl H, 2001. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob Agents Chemother 45: 1505–1510.
Navarrete-Vazquez G, Cedillo R, Hernandez-Campos A, Yepez L, Hernadez-Luis F, Valdez J, Morales R, Cortes R, Hernandez M, Castillo R, 2001. Synthesis and antiparasitic activity of 2-(trifluoromethyl)-benzimidazole derivatives. Bioorg Med Chem Lett 11: 187–190.
Makioka A, Kumagai M, Kobayashi S, Takeuchi T, 2002. Possible role of calcium ions, calcium channels and calmodulin in excystation and metacystic development of Entamoeba invadens. Parasitol Res 88: 837–843.
Ranque S, Gazin P, Delmont J, 2004. Schistosomiasis and tourism in the Dogon country, Mali. Med Trop (Mars) 64: 31–32.
Abid M, Azam A, 2005. 1-N-substituted thiocarbamoyl-3-phenyl-2-pyrazolines: synthesis and in vitro antiamoebic activities. Eur J Med Chem 40: 935–942.
Sawangjaroen N, Phongpaichit S, Subhadhirasakul S, Visutthi M, Srisuwan N, Thammapalerd N, 2006. The anti-amoebic activity of some medicinal plants used by AIDS patients in southern Thailand. Parasitol Res 98: 588–592.
Tasanor O, Brem B, Leitsch D, Binder M, Duchene M, Greger H, Wernsdorfer WH, 2007. Development of a pharmacodynamic screening model with Entamoeba histolytica. Wien Klin Wochenschr 119: 88–95.
Bhat AR, Athar F, Azam A, 2009. New derivatives of 3,5-substituted-1,4,2-dioxazoles: synthesis and activity against Entamoeba histolytica. Eur J Med Chem 44: 926–936.
Neal RA, 1983. Experimental amoebiasis and the development of anti-amoebic compounds. Parasitology 86: 175–191.
Kimura M, Nakamura T, Nawa Y, 2007. Experience with intravenous metronidazole to treat moderate-to-severe amebiasis in Japan. Am J Trop Med Hyg 77: 381–385.
Kaur J, Mathur TN, 1972. Comparative drug trials in symptomatic and asymptomatic non-dysenteric amoebic colitis. Indian J Med Res 60: 1547–1553.
Downey AS, Chong CR, Graczyk TK, Sullivan DJ, 2008. Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model. Antimicrob Agents Chemother 52: 3106–3112.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||311||100||0|
Nitroimidazole antibiotics are the mainstay of treatment of invasive amebiasis; however, few comparative studies of applicable antibiotics are available. Evidence of sporadic clinical failure and rare reports of metronidazole resistance have led to the investigation of novel antiamebic therapeutics. The goal of this study was to examine drug efficacy in both in vitro and in vivo models of intestinal amebiasis. We studied six current and three novel drugs. Many drugs, including metronidazole, nitazoxanide, and nitazoxanide derivatives, were shown to be potently inhibitory in vitro. However, metronidazole remained the most effective in vivo, both in preventative and curative regimens, underscoring the value of animal models in evaluating future therapies.
Financial support: This work was supported by National Institutes of Health Grants AI071373 and AI075520 (to P.H.).
Authors' addresses: Stephen Becker, Paul Hoffman, and Eric R. Houpt, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, E-mails: email@example.com, firstname.lastname@example.org, and email@example.com.